Monte Rosa Therapeutics, Inc. GLUE Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s shares (diluted)?
- Monte Rosa Therapeutics, Inc. (GLUE) reported shares (diluted) of 99.9M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s shares (diluted) changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s shares (diluted) increased by 20.4% year-over-year, from 83M to 99.9M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s shares (diluted)?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s shares (diluted) has grown at a 43.6% compound annual growth rate (CAGR), from 77.8M to 330.6M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.